ABHH,
Está em tempo de participar! A Consulta Pública nº 139 se encerrará amanhã, dia 30/10. Zanubrutinibe já possui quatro aprovações…
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of attention for article published in New England Journal of Medicine, December 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (82nd percentile)
Mentioned by
- news
- 63 news outlets
- blogs
- 2 blogs
- policy
- 3 policy sources
- 112 X users
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- 1 Redditor
- guideline
- 5 clinical guideline sources
- podcasts
- 2 podcasts
Readers on
- mendeley
- 291 Mendeley